The current CE-mark applies to the professional use of the test platform Egoo.Health for sale on the European market.
Qlife commences trading on Nasdaq First North Growth Market
Qlife Holding AB announces that the trading in the company’s shares (short name: QLIFE) will commence today on the Nasdaq First North Growth Market in Stockholm. Qlife Holding AB (“Qlife”) belongs to the health care sector and is the 6[th] company to be admitted to trading on Nasdaq’s Nordic markets* in 2020.
Qlife (https://qlifeholding.com/sv/home) is a high-tech medical device company that seeks to revolutionize the clinical biomarker testing of whole blood by taking it out of the lab and into the homes of the people who needs it the most. Its main product, The Egoo Home System, is an integrated platform consisting of a small home device and disposable capsules, each of which tests for a specific biomarker. It provides a digital infrastructure for sharing the data with the patient’s doctor, clinic or hospital via smartphone and computer. Qlife is headquartered in Helsingborg, Sweden.
“Today is a big milestone for Qlife. Going public has been a journey that would not have been possible if not for the incredible, dedicated team behind Qlife,” said Thomas Warthoe, CEO of Qlife. “I am humbled by the level of interest from investors who can see the same potential in Qlife as we do, and for how they want to help us help others. I am looking forward to developing the company together with my team and create value for customers and investors. There is no doubt that the real journey has just begun.”
“We welcome Qlife to the Nasdaq First North Growth Market,” said Adam Kostyál, SVP and Head of European Listings, Nasdaq. “We continue to see an inflow of innovative health care companies leveraging the Nasdaq First North Growth Market as a platform for growth, and we look forward to supporting Qlife on its continued journey as a publicly listed company.”
Qlife Holding AB has appointed G&W Fondkommission as the Certified Adviser.
*Main markets and the Nasdaq First North Growth Market at Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm
Qlife expects to CE mark its COVID-19 test for professional use in the Egoo.Health system within short.
Since May 2020, Qlife has been handling all testing for COVID-19 for professional football in Denmark.
On November 13, Qlife was informed that the Danish Medicines Agency (Lægemiddelstyrelsen) had rejected the application for temporay approval in Denmark “in the interest of health protection” for th
”We will do our utmost to protect the participating players against the coronavirus”, says Frank Smith, Covid-19 Officer, European Handball Federation Euro 2020 “It requires testing with high preci
Resolution on (A) employee option program; and (B) directed issue of warrants and approval of transfer of warrants
FINANCIAL SUMMARY - THIRD QUARTER 2020
In parallel to the ongoing process of preparing and putting together the dossier for the CE-mark, Qlife has submitted an application for placing the product on the market at this stage, as it offer
The Nomination Committee consists of the following persons, who together represent approximately 39 percent of the company's shares and votes.